Abstract:

BACKGROUND: Previous studies found soybean trypsin inhibitor (SBTI) may have effect on treating diabetes mellitus and regulating insulin disturbance.
OBJECTIVE: To study the effects of SBTI on blood glucose, glucose tolerance, and hepatic glycogen in alloxan diabetic mice.
METHODS: Alloxan diabetic mice models were prepared by intraperitoneal injection of alloxan, and 32 mice with successful model preparation were randomly divided into 4 groups, additional 8 mice were served as control. After model preparation, mice in the SBTI-L and SBTI-H groups were lavaged with 0.27 and 0.80 mg/kg SBTI solution, those in the glibenclamide group was lavaged with 0.16 g/kg glibenclamide. Saline was lavaged in the model and control groups. The medication lasted for 2 weeks. The blood glucose and glucose tolerance of mice were measured by using glucose oxidase method, and the content of hepatic glycogen was determined by the improved anthrone method.
RESULTS AND CONCLUSION: Compared with the model group, the blood glucose of glibenclamide, SBTI-L, and SBTI-H groups was significantly decreased (P < 0.05), and the glucose tolerance rise lower (P < 0.05), but the hepatic glycogen increased obviously (P < 0.05). The SBTI-L and SBTI-H groups showed faster effect and longer effectiveness than the glibenclamide group, especially more manifest in the SBTI-H group. Experimental results show that SBTI can significantly decrease blood glucose, improve glucose tolerance, and increase the content of hepatic glycogen.